Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Open Access
- 31 August 2026
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1460
Abstract
Background Type 2 diabetes mellitus (T2DM) remains a major global health burden. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide improve glycemic control and promote weight loss, many patients do not achieve optimal metabolic targets. Mazdutide, a dual GLP-1 and glucagon receptor agonist, may provide greater efficacy. This systematic review and meta-analysis compared the efficacy and safety of mazdutide versus dulaglutide in adults with T2DM. Methods PubMed, Embase, Cochrane Library, and ScienceDirect were searched through May 2026 for randomized controlled trials comparing mazdutide with dulaglutide. Outcomes included glycemic control, weight loss, cardiometabolic parameters, and safety. Data were pooled using fixed- or random-effects models according to heterogeneity, and certainty of evidence was assessed using the GRADE framework. Results Three RCTs involving 990 participants (mazdutide, n=683; dulaglutide, n=307) were included. Mazdutide significantly reduced HbA1c (mean difference [MD] −0.25%; 95% CI −0.38 to −0.12; p=0.0002) and body weight (MD −3.74%; 95% CI −5.29 to −2.19; p<0.00001) compared with dulaglutide. It also increased the likelihood of achieving ≥5% and ≥10% weight loss and improved blood pressure and triglyceride levels. No significant differences were observed in fasting plasma glucose or HbA1c target achievement (<7%). Treatment-emergent adverse events were more frequent with mazdutide (OR 1.69; 95% CI 1.16–2.45), mainly due to gastrointestinal effects, while serious adverse events were similar between groups. GRADE certainty was high for primary efficacy outcomes, moderate for most safety outcomes, and low to very low for infrequent adverse events. Conclusions Mazdutide demonstrated superior glycemic control, weight reduction, and cardiometabolic benefits compared with dulaglutide, with more frequent but generally mild gastrointestinal adverse events. These findings support mazdutide as a promising treatment option for T2DM, although longer-term comparative studies are needed.Keywords
This publication has 37 references indexed in Scilit:
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With ObesityJAMA, 2026
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesNature, 2025
- Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity DrugsCurrent Obesity Reports, 2025
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysisEBioMedicine, 2025
- Incretin-based therapies for the treatment of obesity-related diseasesnpj Metabolic Health and Disease, 2024
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesityNature Communications, 2023
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trialeClinicalMedicine, 2022
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetesNature Communications, 2022
- Effects of GLP-1 on appetite and weightReviews in Endocrine and Metabolic Disorders, 2014